Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition
Ranjit K. Goudar(Duke Medical Center), Jeremy N. Rich(University of North Carolina at Chapel Hill), Elizabeth D. Reese, Stephen T. Keir(Duke University), Peter Traxler(Novartis (Switzerland)), Mark D. Hjelmeland, Henry S. Friedman(Duke University), David A. Reardon(Dana-Farber Cancer Institute), Webster K. Cavenee(University of California San Diego), Roger E. McLendon(Duke University), Heidi A. Lane(Basilea Pharmaceutica (Switzerland)), Carol J. Wikstrand(Duke University), Charles A. Conrad(The University of Texas MD Anderson Cancer Center), Qing Shi, Xiao-Fan Wang(Xi'an University of Science and Technology), Darell D. Bigner(Duke Medical Center)
Cited by 245
Related Papers
Mutations of the BRAF gene in human cancer
|Nature|2002|10.7k
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
|Nature|2008|7.8k
The Somatic Genomic Landscape of Glioblastoma
|Cell|2013|5.2k
Malignant astrocytic glioma: genetics, biology, and paths to treatment
|Genes & Development|2007|2.3k
The WHO Classification of Tumors of the Nervous System
|Journal of Neuropathology & Experimental Neurology|2002|2k